 southwest oncolog group studi use human tumor assay respons patient ovarian cancer total patient epitheli ovarian cancer tumor chemotherapi prior chemotherapi differ southwest oncolog group institut tumor specimen central laboratori drug-sensit test human tumor assay patient prior histori chemotherapi failur median prior chemotherapeut agent effect agent clone assay patient patient tumor coloni vitro sensit agent clinician choic agent patient patient chemotherapi perform statu earli death complet partial respons rate patient result patient clinician choic signific differ surviv option versu month patient histori prior chemotherapi standard combin chemotherapi clinic respons vitro sensit agent true-posit rate true-neg rate evalu patient data author use human tumor assay respons rate surviv patient advanc chemotherapy-refractori ovarian cancer studi mani step patient select inadequ tumor coloni format vitro inabl patient earli death rapid declin perform statu assay worthi addit studi respons combin chemotherapi patient prior histori chemotherapi use central chemosensit laboratori feasibl vitro predict assay cooper group